Search

A recent study from the University Hospital Center in Lisbon, Portugal, highlights the importance of addressing coronary and structural heart disease in cancer patients. While there has been increased awareness of cardiotoxicity in cancer patients, the focus has primarily been on myocardial systolic dysfunction and heart failure. Limited evidence and guidelines exist for dealing with coronary and structural heart disease in this population. To address this gap, the Portuguese Association of Cardiovascular Intervention and the Cardio-Oncology Study Group of the Portuguese Society of Cardiology have collaborated to produce a position paper on cardiac intervention in cancer patients, with a focus on percutaneous techniques. The paper provides a brief review of available evidence and practical considerations based on the authors' experience in the field. [Extracted from the article]

Researchers from Chaudhary Charan Singh University in India have developed a paper-based analytical device for the early detection of ovarian cancer. The device uses silver nanoparticles coated on paper to detect lysophosphatidic acid (LPA), a biomarker for ovarian cancer, through surface enhanced Raman spectroscopy (SERS). The study found that patients with ovarian cancer had higher levels of LPA compared to those with benign ovarian tumors or healthy individuals. The researchers believe that this point-of-care device could be a simple, effective, and cost-effective tool for early diagnosis of ovarian cancer. [Extracted from the article]

A recent study conducted by researchers at the Vellore Institute of Technology in Tamil Nadu, India, explores the concept of biographical renewal in cancer survivorship. The study highlights the positive transformations that can occur after cancer and emphasizes the importance of considering biographical renewal as a goal in survivorship care plans. The researchers suggest that healthcare professionals, caregivers, and palliative care providers should strive to foster an understanding of biographical renewal to provide comprehensive care and improve patients' quality of life. The study's findings are published in the Indian Journal of Palliative Care. [Extracted from the article]

Queen's University researchers have developed an educational resource for gynecological cancer survivors and their caregivers. The resource was created through a patient-clinician-researcher partnership and involved five phases, including assembling expertise, reviewing literature, drafting the resource, testing it, and disseminating it. The researchers used diverse partnerships and multiple research methods to create a resource that fills a procedural gap for clinicians and researchers looking to develop empirically and experientially founded educational resources. For more information, readers can refer to the article "Developing an educational resource for gynecological cancer survivors and their caregivers: A methods and experience paper" in the Canadian Oncology Nursing Journal. [Extracted from the article]

A recent report from Memorial Sloan-Kettering Cancer Center in New York City compared the use of electronic informed consent (eIC) to traditional paper consent in clinical trials. The study found that eIC did not increase the burden of technology, supported comparable comprehension of the consent process, upheld participant agency, and increased completion of required consent fields. Participants reported that eIC was easy to use and generated positive feedback regarding the thoroughness of the discussion and professionalism of the consenters. The findings suggest that offering eIC for clinical research discussions can enhance the participant experience and improve the completeness of the consent process. [Extracted from the article]

Researchers at Mendel University Brno in the Czech Republic have developed a novel, noninvasive method for detecting and diagnosing prostate cancer (CaP) using urine samples and a paper-based analytical device. The method involves detecting UV-induced fluorescent clusters in the urine samples that are specific to CaP patients using fluorescence spectroscopy. The researchers were able to correctly distinguish between CaP patients and controls, as well as determine the different stages of the disease. This easy-to-operate, point-of-care assay shows promise for early diagnosis of CaP with high accuracy and could potentially be applied to other diseases and disorders. [Extracted from the article]

A joint position paper on molecular tumor boards (MTBs) in Taiwan has been published by the Taiwan Oncology Society (TOS) and the Taiwan Society of Pathology (TSP). The paper, formulated by 20 experts from TOS and TSP, aims to raise awareness of MTBs among healthcare professionals, policymakers, and the public. The paper proposes key recommendations for MTB discussions, including the incorporation of diverse molecular analyses, involvement of multidisciplinary participants, prioritization of cases with unique clinical needs, and the use of comprehensive patient data. The primary goal of this initiative is to promote the advancement of precision oncology in Taiwan. [Extracted from the article]

HanxBio has published a research paper titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the journal Scientific Reports. The paper describes the preclinical evaluation of Narazaciclib (HX301) for the treatment of acute myeloid leukemia (AML). The researchers conducted comprehensive pharmacology characterization of HX301 using various preclinical experimental AML models, demonstrating its strong anti-leukemia activity and potential mechanisms of action. The study also investigated the pharmacodynamics and pharmacokinetics of HX301, providing valuable information for clinical dosage selection. The results of this study will guide the clinical development strategies for HX301 in the treatment of AML. [Extracted from the article]